Ventas VTR OM&R — Impairment of real estate
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ventas in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfRealEstate.
The official record: Ventas’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ventas's om&r — impairment of real estate.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ventas's OM&R — impairment of real estate?
- Ventas (VTR) reported OM&R — impairment of real estate of $22.2M in Q1 2026.
- How has Ventas's OM&R — impairment of real estate changed year-over-year?
- Ventas's OM&R — impairment of real estate increased by 54.2% year-over-year, from $14.4M to $22.2M.
- What is the long-term trend for Ventas's OM&R — impairment of real estate?
- Over 3 years (2022 to 2025), Ventas's OM&R — impairment of real estate has grown at a 27.6% compound annual growth rate (CAGR), from $27.5M to $57.1M.
- What does OM&R — impairment of real estate mean?
- The non-cash charge recognized when the carrying value of an Outpatient Medical and Research property exceeds its fair market value. This metric highlights assets that are underperforming or facing market headwinds. Frequent or large impairments can indicate poor underwriting or deteriorating market conditions in the medical office sector.